Evaluation of PASI Before and After Combined Treatment in Mild to Moderate Psoriasis

Abstract

Background. - Plaque psoriasis is a disease of immunological origin that damages the skin, mucous membranes. Biological therapies combined with systemic medications are effective in treating plaque psoriasis. Our objective was to evaluate the treatment of Etanercept with methotrexate and to verify its response with the PASI index in its initial and control phase. Methodology. - The Universe of patient treated at the Military Hospital in Guayaquil was 2.620 corresponding from January until July 2020; the selected sample according to the inclusion criteria was 94 patients with plaque psoriasis. The method was retrospective, observational, descriptive, cross-sectional, correlational differential analytical. Result. - In this study, the prevalence was 3.58%, The BMI index was 28.13 corresponding to overweight and obesity. The PASI index in the initial stage before treatment showed 10.8% and in the control phase, it fell to 2.99%, showing a decrease in lesions and good improvement to the combined treatment. In Student´s T, the combination of Etanercept with Methotrexate was compared with de evolution of PASI index, in the initial and control phases, presenting a value lower than 0.001 < P = 0.05, this response being very significant Discussion. - In our study, the combination of Etanercept with Methotrexate has a favorable this disease response in reducing this disease. It´s expected that, in Ecuador, the Health Authorities would implement the Biologics for the treatment of plaque psoriasis and including them in the basic list of medicines of the Public Health Ministry.